Author | Scott T. Tagawa, MD | OncLive

Author | Scott T. Tagawa, MD

Articles

Dr. Tagawa on Significance of BRCA2 With PSMA-Targeted Radionuclide Therapy in Prostate Cancer

July 17, 2019

Video

Scott T. Tagawa, MD, discusses the impact of the BRCA2 mutation in patients with prostate cancer who are receiving prostate-specific membrane antigen–targeted radionuclide therapy.

Dr. Tagawa on Next Steps With Sacituzumab Govitecan in Advanced Urothelial Carcinoma

June 17, 2019

Video

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses next steps with sacituzumab govitecan in advanced urothelial carcinoma.

Dr. Tagawa Discusses Darolutamide in CRPC

March 28, 2019

Video

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian-Weill Cornell Medical Center, discusses darolutamide in castration-resistant prostate cancer.

Dr. Tagawa on Sacituzumab Govitecan in Urothelial Carcinoma

February 15, 2019

Video

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses sacituzumab govitecan in the treatment of patients with urothelial carcinoma.

x